A Randomized, Placebo-controlled Trial of DAPAgliflozin for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Hypertensive crisis
- Focus Therapeutic Use
- Acronyms DAPA-HP
- 24 Jan 2025 New trial record